118 related articles for article (PubMed ID: 22018789)
1. Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).
Sessions EH; Chowdhury S; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Dec; 21(23):7113-8. PubMed ID: 22018789
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).
Chowdhury S; Sessions EH; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; Schürer S; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Dec; 21(23):7107-12. PubMed ID: 22004718
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP
ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168
[TBL] [Abstract][Full Text] [Related]
4. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
[TBL] [Abstract][Full Text] [Related]
5. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
[TBL] [Abstract][Full Text] [Related]
6. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
Bosanac T; Hickey ER; Ginn J; Kashem M; Kerr S; Kugler S; Li X; Olague A; Schlyer S; Young ER
Bioorg Med Chem Lett; 2010 Jun; 20(12):3746-9. PubMed ID: 20471253
[TBL] [Abstract][Full Text] [Related]
7. Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
Wu F; Büttner FH; Chen R; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Paw Z; Prokopowicz A; Shih CK; Snow R; Young E; Cywin CL
Bioorg Med Chem Lett; 2010 Jun; 20(11):3235-9. PubMed ID: 20462760
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.
Matter H; Scheiper B; Steinhagen H; Böcskei Z; Fleury V; McCort G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5487-92. PubMed ID: 21840215
[TBL] [Abstract][Full Text] [Related]
9. N-substituted azaindoles as potent inhibitors of Cdc7 kinase.
Bryan MC; Falsey JR; Frohn M; Reichelt A; Yao G; Bartberger MD; Bailis JM; Zalameda L; Miguel TS; Doherty EM; Allen JG
Bioorg Med Chem Lett; 2013 Apr; 23(7):2056-60. PubMed ID: 23481650
[TBL] [Abstract][Full Text] [Related]
10. 4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors.
Liddle J; Bamborough P; Barker MD; Campos S; Cousins RP; Cutler GJ; Hobbs H; Holmes DS; Ioannou C; Mellor GW; Morse MA; Payne JJ; Pritchard JM; Smith KJ; Tape DT; Whitworth C; Williamson RA
Bioorg Med Chem Lett; 2009 May; 19(9):2504-8. PubMed ID: 19349179
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases.
Nishiguchi GA; Atallah G; Bellamacina C; Burger MT; Ding Y; Feucht PH; Garcia PD; Han W; Klivansky L; Lindvall M
Bioorg Med Chem Lett; 2011 Nov; 21(21):6366-9. PubMed ID: 21945284
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors.
Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Mar; 21(6):1844-8. PubMed ID: 21349713
[TBL] [Abstract][Full Text] [Related]
13. Chroman-3-amides as potent Rho kinase inhibitors.
Chen YT; Bannister TD; Weiser A; Griffin E; Lin L; Ruiz C; Cameron MD; Schürer S; Duckett D; Schröter T; LoGrasso P; Feng Y
Bioorg Med Chem Lett; 2008 Dec; 18(24):6406-9. PubMed ID: 18990570
[TBL] [Abstract][Full Text] [Related]
14. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
Sessions EH; Yin Y; Bannister TD; Weiser A; Griffin E; Pocas J; Cameron MD; Ruiz C; Lin L; Schürer SC; Schröter T; LoGrasso P; Feng Y
Bioorg Med Chem Lett; 2008 Dec; 18(24):6390-3. PubMed ID: 18996009
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.
Yin Y; Lin L; Ruiz C; Khan S; Cameron MD; Grant W; Pocas J; Eid N; Park H; Schröter T; Lograsso PV; Feng Y
J Med Chem; 2013 May; 56(9):3568-81. PubMed ID: 23570561
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors.
Scheiper B; Matter H; Steinhagen H; Stilz U; Böcskei Z; Fleury V; McCort G
Bioorg Med Chem Lett; 2010 Nov; 20(21):6268-72. PubMed ID: 20850300
[TBL] [Abstract][Full Text] [Related]
17. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.
Fang X; Yin Y; Chen YT; Yao L; Wang B; Cameron MD; Lin L; Khan S; Ruiz C; Schröter T; Grant W; Weiser A; Pocas J; Pachori A; Schürer S; Lograsso P; Feng Y
J Med Chem; 2010 Aug; 53(15):5727-37. PubMed ID: 20684608
[TBL] [Abstract][Full Text] [Related]
18. Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.
Morwick T; Büttner FH; Cywin CL; Dahmann G; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Mao W; Marshall D; Paw Z; Shih CK; Wu F; Young E
J Med Chem; 2010 Jan; 53(2):759-77. PubMed ID: 20000469
[TBL] [Abstract][Full Text] [Related]
19. Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase.
Liang Z; Zhang D; Ai J; Chen L; Wang H; Kong X; Zheng M; Liu H; Luo C; Geng M; Jiang H; Chen K
Bioorg Med Chem Lett; 2011 Jun; 21(12):3749-54. PubMed ID: 21561768
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.
Kast R; Schirok H; Figueroa-Pérez S; Mittendorf J; Gnoth MJ; Apeler H; Lenz J; Franz JK; Knorr A; Hütter J; Lobell M; Zimmermann K; Münter K; Augstein KH; Ehmke H; Stasch JP
Br J Pharmacol; 2007 Dec; 152(7):1070-80. PubMed ID: 17934515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
